epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
Apitegromab
apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
Atacicept
atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Invokana

canagliflozin

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  TAB: 100 mg, 300 mg

diabetes mellitus, type 2

[100-300 mg PO qd]
Start: 100 mg PO qd; Max: 300 mg/day; Info: give before 1st meal; hold tx at least 3 days before surgery/procedure if prolonged fasting

cardiovascular event risk reduction - DM type 2 patients with established cardiovascular disease

[100 mg PO qd]
Max: 300 mg/day; Info: give before 1st meal; may incr. dose to 300 mg PO qd if additional glycemic control needed; hold tx at least 3 days before surgery/procedure if prolonged fasting

kidney disease progression and cardiovascular-associated risk reduction - DM type 2 patients with nephropathy and albuminuria >300 mg/day

[100 mg PO qd]
Max: 300 mg/day; Info: give before 1st meal; may incr. dose to 300 mg PO qd if additional glycemic control needed; hold tx at least 3 days before surgery/procedure if prolonged fasting

renal dosing

[diabetes mellitus, type 2]
eGFR 30-59: max 100 mg/day; eGFR <30: avoid use for glycemic control
HD/PD: not defined
[all other indications]
eGFR 30-59: max 100 mg/day; eGFR <30: avoid tx initiation; Info: if eGFR <30 during tx, may continue 100 mg qd in patients with albuminuria >300 mg/day
HD/PD: not defined

hepatic dosing

[see below]
Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Peds Dosing .

Dosage forms:  TAB: 100 mg, 300 mg

diabetes mellitus, type 2

[10 yo and older]
Dose: 100-300 mg PO qd; Start: 100 mg PO qd; Max: 300 mg/day; Info: give before 1st meal; hold tx at least 3 days before surgery/procedure if prolonged fasting

renal dosing

[see below]
eGFR 30-59: max 100 mg/day; eGFR <30: avoid use for glycemic control
HD/PD: not defined

hepatic dosing

[see below]
Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@4a1dccf0
  • hypersensitivity to drug or ingredient
  • pregnancy 2nd trimester
  • pregnancy 3rd trimester
  • breastfeeding
  • eGFR <30
  • caution: elderly patients
  • diabetic ketoacidosis
  • volume depletion
  • caution: pregnancy 1st trimester
  • caution: eGFR <60
  • caution: hypotension
  • caution: ketoacidosis risk
  • caution: pancreatic disorder
  • caution: fasting
  • caution: febrile illness, acute
  • caution: surgery
  • caution: ketogenic diet
  • caution: alcohol abuse
  • caution: genital mycotic infection history
  • caution: uncircumcised penis
  • caution: fracture risk
  • caution: amputation history
  • caution: PVD
  • caution: neuropathy
  • caution: diabetic foot ulcer
  • caution: osteomyelitis
  • caution: gangrene

Drug Interactions .

Overview

canagliflozin

SGLT2 inhibitor

Interaction Characteristics:
  • UGT1A9 substrate
  • UGT2B4 substrate
  • P-gp inhibitor, weak
  • antidiabetic agent
  • fluid/electrolyte loss
  • hypotensive effects

Contraindicated

  • colchicine
  • Invokana (canagliflozin)
    +
    colchicine
    1 interaction

    Contraindicated

    canagliflozin + colchicine

    CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after canagliflozin use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (P-gp-mediated transport inhibited)

Avoid/Use Alternative

  • aldesleukin
  • Invokana (canagliflozin)
    +
    aldesleukin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + aldesleukin

    avoid combo: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • apixaban
  • Invokana (canagliflozin)
    +
    apixaban
    1 interaction

    Avoid/Use Alternative

    canagliflozin + apixaban

    ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • bexagliflozin
  • Invokana (canagliflozin)
    +
    bexagliflozin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + bexagliflozin

    avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • canagliflozin
  • Invokana (canagliflozin)
    +
    canagliflozin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + canagliflozin

    avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • dabigatran
  • Invokana (canagliflozin)
    +
    dabigatran
    1 interaction

    Avoid/Use Alternative

    canagliflozin + dabigatran

    ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

  • dapagliflozin
  • Invokana (canagliflozin)
    +
    dapagliflozin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + dapagliflozin

    avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • empagliflozin
  • Invokana (canagliflozin)
    +
    empagliflozin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + empagliflozin

    avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • ensartinib
  • Invokana (canagliflozin)
    +
    ensartinib
    1 interaction

    Avoid/Use Alternative

    canagliflozin + ensartinib

    avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects; may decr. antidiabetic agent efficacy (P-gp-mediated transport possibly inhibited; antagonistic effects)

  • ertugliflozin
  • Invokana (canagliflozin)
    +
    ertugliflozin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + ertugliflozin

    avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • lofexidine
  • Invokana (canagliflozin)
    +
    lofexidine
    1 interaction

    Avoid/Use Alternative

    canagliflozin + lofexidine

    use alternative or monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • neratinib
  • Invokana (canagliflozin)
    +
    neratinib
    1 interaction

    Avoid/Use Alternative

    canagliflozin + neratinib

    avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • pralsetinib
  • Invokana (canagliflozin)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    canagliflozin + pralsetinib

    use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ strong CYP3A4 inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

  • relugolix
  • Invokana (canagliflozin)
    +
    relugolix
    1 interaction

    Avoid/Use Alternative

    canagliflozin + relugolix

    PROSTATE CANCER: may hold relugolix if canagliflozin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before canagliflozin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before canagliflozin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

  • repotrectinib
  • Invokana (canagliflozin)
    +
    repotrectinib
    1 interaction

    Avoid/Use Alternative

    canagliflozin + repotrectinib

    avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • rivaroxaban
  • Invokana (canagliflozin)
    +
    rivaroxaban
    1 interaction

    Avoid/Use Alternative

    canagliflozin + rivaroxaban

    avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • sirolimus albumin-bound
  • Invokana (canagliflozin)
    +
    sirolimus albumin-bound
    1 interaction

    Avoid/Use Alternative

    canagliflozin + sirolimus albumin-bound

    avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. antidiabetic agent efficacy (P-gp-mediated transport inhibited; antagonistic effects)

  • sotagliflozin
  • Invokana (canagliflozin)
    +
    sotagliflozin
    1 interaction

    Avoid/Use Alternative

    canagliflozin + sotagliflozin

    avoid combo: combo may incr. risk of hypoglycemia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • topotecan
  • Invokana (canagliflozin)
    +
    topotecan
    1 interaction

    Avoid/Use Alternative

    canagliflozin + topotecan

    avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

  • venetoclax
  • Invokana (canagliflozin)
    +
    venetoclax
    1 interaction

    Avoid/Use Alternative

    canagliflozin + venetoclax

    monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

Monitor/Modify Tx

  • acebutolol
  • Invokana (canagliflozin)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + acebutolol

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • afatinib
  • Invokana (canagliflozin)
    +
    afatinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + afatinib

    decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • alclometasone topical
  • Invokana (canagliflozin)
    +
    alclometasone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + alclometasone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • alfentanil
  • Invokana (canagliflozin)
    +
    alfentanil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + alfentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • alfuzosin
  • Invokana (canagliflozin)
    +
    alfuzosin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + alfuzosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aliskiren
  • Invokana (canagliflozin)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aliskiren

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aloe
  • Invokana (canagliflozin)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aloe

    monitor glucose w/ oral aloe: combo may incr. risk of hypoglycemia (additive effects)

  • alogliptin
  • Invokana (canagliflozin)
    +
    alogliptin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + alogliptin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • alpelisib
  • Invokana (canagliflozin)
    +
    alpelisib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + alpelisib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • alprostadil intracavernous
  • Invokana (canagliflozin)
    +
    alprostadil intracavernous
    1 interaction

    Monitor/Modify Tx

    canagliflozin + alprostadil intracavernous

    monitor BP: combo may increase risk of hypotension, including orthostasis, syncope (additive effects)

  • amantadine
  • Invokana (canagliflozin)
    +
    amantadine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amantadine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amcinonide topical
  • Invokana (canagliflozin)
    +
    amcinonide topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amcinonide topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • amifostine
  • Invokana (canagliflozin)
    +
    amifostine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amifostine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • amiloride
  • Invokana (canagliflozin)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amiloride

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amitriptyline
  • Invokana (canagliflozin)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amitriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amlodipine
  • Invokana (canagliflozin)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amlodipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amoxapine
  • Invokana (canagliflozin)
    +
    amoxapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + amoxapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • apomorphine
  • Invokana (canagliflozin)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + apomorphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • apraclonidine ophthalmic
  • Invokana (canagliflozin)
    +
    apraclonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + apraclonidine ophthalmic

    monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aprocitentan
  • Invokana (canagliflozin)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aprocitentan

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aripiprazole bimonthly injection
  • Invokana (canagliflozin)
    +
    aripiprazole bimonthly injection
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aripiprazole bimonthly injection

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • aripiprazole lauroxil
  • Invokana (canagliflozin)
    +
    aripiprazole lauroxil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aripiprazole lauroxil

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • aripiprazole monthly injection
  • Invokana (canagliflozin)
    +
    aripiprazole monthly injection
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aripiprazole monthly injection

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • aripiprazole oral
  • Invokana (canagliflozin)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aripiprazole oral

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • arsenic trioxide
  • Invokana (canagliflozin)
    +
    arsenic trioxide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + arsenic trioxide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • articaine
  • Invokana (canagliflozin)
    +
    articaine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + articaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • asenapine
  • Invokana (canagliflozin)
    +
    asenapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + asenapine

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • ashwagandha
  • Invokana (canagliflozin)
    +
    ashwagandha
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ashwagandha

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • asparaginase
  • Invokana (canagliflozin)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    canagliflozin + asparaginase

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • aspirin
  • Invokana (canagliflozin)
    +
    aspirin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + aspirin

    monitor glucose, especially w/ high-dose aspirin: combo may incr. risk of hypoglycemia (additive effects)

  • atazanavir
  • Invokana (canagliflozin)
    +
    atazanavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + atazanavir

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • atenolol
  • Invokana (canagliflozin)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + atenolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • atorvastatin
  • Invokana (canagliflozin)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + atorvastatin

    monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited)

  • avanafil
  • Invokana (canagliflozin)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + avanafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • azilsartan medoxomil
  • Invokana (canagliflozin)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + azilsartan medoxomil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • benazepril
  • Invokana (canagliflozin)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + benazepril

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • berberine
  • Invokana (canagliflozin)
    +
    berberine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + berberine

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • betamethasone
  • Invokana (canagliflozin)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + betamethasone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • betamethasone topical
  • Invokana (canagliflozin)
    +
    betamethasone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + betamethasone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • betaxolol
  • Invokana (canagliflozin)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + betaxolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • betaxolol ophthalmic
  • Invokana (canagliflozin)
    +
    betaxolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + betaxolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bethanechol
  • Invokana (canagliflozin)
    +
    bethanechol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bethanechol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bismuth subsalicylate
  • Invokana (canagliflozin)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bismuth subsalicylate

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • bisoprolol
  • Invokana (canagliflozin)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bisoprolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bortezomib
  • Invokana (canagliflozin)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bortezomib

    monitor BP, glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia, severe hypotension, including orthostasis, syncope (additive effects, antagonistic effects)

  • brentuximab vedotin
  • Invokana (canagliflozin)
    +
    brentuximab vedotin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + brentuximab vedotin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • brexpiprazole
  • Invokana (canagliflozin)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    canagliflozin + brexpiprazole

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • brigatinib
  • Invokana (canagliflozin)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + brigatinib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • brimonidine ophthalmic
  • Invokana (canagliflozin)
    +
    brimonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + brimonidine ophthalmic

    monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of hypotension, including orthostasis, syncope (additive effects)

  • brimonidine topical
  • Invokana (canagliflozin)
    +
    brimonidine topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + brimonidine topical

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bromocriptine
  • Invokana (canagliflozin)
    +
    bromocriptine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bromocriptine

    monitor BP, glucose if type 2 diabetes mellitus use: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • budesonide
  • Invokana (canagliflozin)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + budesonide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • bumetanide
  • Invokana (canagliflozin)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bumetanide

    monitor glucose, electrolytes, volume status, renal fxn, BP: combo may incr. risk of electrolyte abnormalities, dehydration, hypovolemia, renal impairment, hypotension (including orthostasis, syncope), other adverse effects; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • bupivacaine
  • Invokana (canagliflozin)
    +
    bupivacaine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bupivacaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bupivacaine liposomal
  • Invokana (canagliflozin)
    +
    bupivacaine liposomal
    1 interaction

    Monitor/Modify Tx

    canagliflozin + bupivacaine liposomal

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • buprenorphine
  • Invokana (canagliflozin)
    +
    buprenorphine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + buprenorphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • butalbital
  • Invokana (canagliflozin)
    +
    butalbital
    1 interaction

    Monitor/Modify Tx

    canagliflozin + butalbital

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced)

  • butorphanol
  • Invokana (canagliflozin)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + butorphanol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cabergoline
  • Invokana (canagliflozin)
    +
    cabergoline
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cabergoline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • calaspargase
  • Invokana (canagliflozin)
    +
    calaspargase
    1 interaction

    Monitor/Modify Tx

    canagliflozin + calaspargase

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • candesartan cilexetil
  • Invokana (canagliflozin)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + candesartan cilexetil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cannabis
  • Invokana (canagliflozin)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cannabis

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • capivasertib
  • Invokana (canagliflozin)
    +
    capivasertib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + capivasertib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • captopril
  • Invokana (canagliflozin)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + captopril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • carbamazepine
  • Invokana (canagliflozin)
    +
    carbamazepine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + carbamazepine

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced)

  • cariprazine
  • Invokana (canagliflozin)
    +
    cariprazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cariprazine

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • carteolol ophthalmic
  • Invokana (canagliflozin)
    +
    carteolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + carteolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • carvedilol
  • Invokana (canagliflozin)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + carvedilol

    monitor BP, glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia, hypotension, including orthostasis, syncope (additive effects, antagonistic effects)

  • cassia cinnamon
  • Invokana (canagliflozin)
    +
    cassia cinnamon
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cassia cinnamon

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • ceritinib
  • Invokana (canagliflozin)
    +
    ceritinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ceritinib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • chloroprocaine
  • Invokana (canagliflozin)
    +
    chloroprocaine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + chloroprocaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • chloroquine
  • Invokana (canagliflozin)
    +
    chloroquine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + chloroquine

    monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

  • chlorothiazide
  • Invokana (canagliflozin)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + chlorothiazide

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • chlorpromazine
  • Invokana (canagliflozin)
    +
    chlorpromazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + chlorpromazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • chlorthalidone
  • Invokana (canagliflozin)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + chlorthalidone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • chromium
  • Invokana (canagliflozin)
    +
    chromium
    1 interaction

    Monitor/Modify Tx

    canagliflozin + chromium

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • cilostazol
  • Invokana (canagliflozin)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cilostazol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ciprofloxacin
  • Invokana (canagliflozin)
    +
    ciprofloxacin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ciprofloxacin

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, including life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

  • clarithromycin
  • Invokana (canagliflozin)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clarithromycin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • clevidipine
  • Invokana (canagliflozin)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clevidipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • clobetasol topical
  • Invokana (canagliflozin)
    +
    clobetasol topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clobetasol topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • clocortolone topical
  • Invokana (canagliflozin)
    +
    clocortolone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clocortolone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • clofarabine
  • Invokana (canagliflozin)
    +
    clofarabine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clofarabine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • clomipramine
  • Invokana (canagliflozin)
    +
    clomipramine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clomipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • clonidine
  • Invokana (canagliflozin)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clonidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • clozapine
  • Invokana (canagliflozin)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + clozapine

    monitor BP, HR, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • codeine
  • Invokana (canagliflozin)
    +
    codeine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + codeine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • coenzyme Q-10
  • Invokana (canagliflozin)
    +
    coenzyme Q-10
    1 interaction

    Monitor/Modify Tx

    canagliflozin + coenzyme Q-10

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • colesevelam
  • Invokana (canagliflozin)
    +
    colesevelam
    1 interaction

    Monitor/Modify Tx

    canagliflozin + colesevelam

    monitor glucose if type 2 diabetes mellitus use: combo may incr. risk of hypoglycemia (additive effects)

  • copanlisib
  • Invokana (canagliflozin)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + copanlisib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects, copanlisib may cause infusion-related hyperglycemia)

  • corticotropin
  • Invokana (canagliflozin)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + corticotropin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • cortisone
  • Invokana (canagliflozin)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cortisone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • cyclosporine
  • Invokana (canagliflozin)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + cyclosporine

    monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited)

  • dabrafenib
  • Invokana (canagliflozin)
    +
    dabrafenib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dabrafenib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • danazol
  • Invokana (canagliflozin)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + danazol

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • darunavir
  • Invokana (canagliflozin)
    +
    darunavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + darunavir

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • decitabine
  • Invokana (canagliflozin)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + decitabine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • deflazacort
  • Invokana (canagliflozin)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    canagliflozin + deflazacort

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • delafloxacin
  • Invokana (canagliflozin)
    +
    delafloxacin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + delafloxacin

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, including life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

  • denileukin diftitox
  • Invokana (canagliflozin)
    +
    denileukin diftitox
    1 interaction

    Monitor/Modify Tx

    canagliflozin + denileukin diftitox

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • desflurane
  • Invokana (canagliflozin)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    canagliflozin + desflurane

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • desipramine
  • Invokana (canagliflozin)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + desipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • desogestrel (contraceptive)
  • Invokana (canagliflozin)
    +
    desogestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + desogestrel (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • desonide topical
  • Invokana (canagliflozin)
    +
    desonide topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + desonide topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • desoximetasone topical
  • Invokana (canagliflozin)
    +
    desoximetasone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + desoximetasone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • dexamethasone
  • Invokana (canagliflozin)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dexamethasone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • dexmedetomidine
  • Invokana (canagliflozin)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dexmedetomidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dexmedetomidine injection
  • Invokana (canagliflozin)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dexmedetomidine injection

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • diazoxide
  • Invokana (canagliflozin)
    +
    diazoxide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + diazoxide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • dienogest (contraceptive)
  • Invokana (canagliflozin)
    +
    dienogest (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dienogest (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • diflorasone topical
  • Invokana (canagliflozin)
    +
    diflorasone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + diflorasone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • digoxin
  • Invokana (canagliflozin)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + digoxin

    monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

  • dihydrocodeine
  • Invokana (canagliflozin)
    +
    dihydrocodeine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dihydrocodeine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • diltiazem
  • Invokana (canagliflozin)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    canagliflozin + diltiazem

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dinutuximab
  • Invokana (canagliflozin)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dinutuximab

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dipyridamole
  • Invokana (canagliflozin)
    +
    dipyridamole
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dipyridamole

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • disopyramide
  • Invokana (canagliflozin)
    +
    disopyramide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + disopyramide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • doxazosin
  • Invokana (canagliflozin)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + doxazosin

    monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • doxepin
  • Invokana (canagliflozin)
    +
    doxepin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + doxepin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dronabinol
  • Invokana (canagliflozin)
    +
    dronabinol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + dronabinol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • drospirenone (contraceptive)
  • Invokana (canagliflozin)
    +
    drospirenone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + drospirenone (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • duloxetine
  • Invokana (canagliflozin)
    +
    duloxetine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + duloxetine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • edoxaban
  • Invokana (canagliflozin)
    +
    edoxaban
    1 interaction

    Monitor/Modify Tx

    canagliflozin + edoxaban

    monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • eleuthero
  • Invokana (canagliflozin)
    +
    eleuthero
    1 interaction

    Monitor/Modify Tx

    canagliflozin + eleuthero

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • enalapril
  • Invokana (canagliflozin)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + enalapril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • enalaprilat
  • Invokana (canagliflozin)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    canagliflozin + enalaprilat

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • enfortumab vedotin
  • Invokana (canagliflozin)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + enfortumab vedotin

    monitor glucose; if also combined w/ strong CYP3A4 inhibitor, monitor CBC: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects; may decr. antidiabetic agent efficacy (P-gp-mediated transport inhibited; antagonistic effects)

  • entacapone
  • Invokana (canagliflozin)
    +
    entacapone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + entacapone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • entrectinib
  • Invokana (canagliflozin)
    +
    entrectinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + entrectinib

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ephedra
  • Invokana (canagliflozin)
    +
    ephedra
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ephedra

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • epinephrine
  • Invokana (canagliflozin)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + epinephrine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • eplerenone
  • Invokana (canagliflozin)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + eplerenone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • epoprostenol
  • Invokana (canagliflozin)
    +
    epoprostenol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + epoprostenol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • esmolol
  • Invokana (canagliflozin)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + esmolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • estetrol (contraceptive)
  • Invokana (canagliflozin)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + estetrol (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • estradiol (contraceptive)
  • Invokana (canagliflozin)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + estradiol (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • estradiol (hormone replacement)
  • Invokana (canagliflozin)
    +
    estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + estradiol (hormone replacement)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • estrogens, conjugated (hormone replacement)
  • Invokana (canagliflozin)
    +
    estrogens, conjugated (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + estrogens, conjugated (hormone replacement)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • estrogens, esterified (hormone replacement)
  • Invokana (canagliflozin)
    +
    estrogens, esterified (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + estrogens, esterified (hormone replacement)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • ethacrynic acid
  • Invokana (canagliflozin)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethacrynic acid

    monitor volume status, renal fxn, BP, glucose: combo may incr. risk of hypovolemia, renal impairment, hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • ethanol (alcoholic beverage)
  • Invokana (canagliflozin)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethanol (alcoholic beverage)

    monitor BP, glucose: combo may incr. risk of severe hypotension (including orthostasis, syncope), hypoglycemia (additive effects)

  • ethanol injection
  • Invokana (canagliflozin)
    +
    ethanol injection
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethanol injection

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • ethinyl estradiol (contraceptive)
  • Invokana (canagliflozin)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethinyl estradiol (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • ethinyl estradiol (hormone replacement)
  • Invokana (canagliflozin)
    +
    ethinyl estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethinyl estradiol (hormone replacement)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • ethionamide
  • Invokana (canagliflozin)
    +
    ethionamide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethionamide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • ethynodiol (contraceptive)
  • Invokana (canagliflozin)
    +
    ethynodiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ethynodiol (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • etonogestrel (contraceptive)
  • Invokana (canagliflozin)
    +
    etonogestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + etonogestrel (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • etripamil nasal
  • Invokana (canagliflozin)
    +
    etripamil nasal
    1 interaction

    Monitor/Modify Tx

    canagliflozin + etripamil nasal

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • everolimus
  • Invokana (canagliflozin)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    canagliflozin + everolimus

    monitor glucose; TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects; may decr. antidiabetic agent efficacy (P-gp-mediated transport inhibited; antagonistic effects)

  • exenatide
  • Invokana (canagliflozin)
    +
    exenatide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + exenatide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • felodipine
  • Invokana (canagliflozin)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + felodipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fenoldopam
  • Invokana (canagliflozin)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fenoldopam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fentanyl
  • Invokana (canagliflozin)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fentanyl

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • fenugreek
  • Invokana (canagliflozin)
    +
    fenugreek
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fenugreek

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • ferumoxytol
  • Invokana (canagliflozin)
    +
    ferumoxytol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ferumoxytol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fexinidazole
  • Invokana (canagliflozin)
    +
    fexinidazole
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fexinidazole

    monitor glucose: combo may decr. canagliflozin levels, efficacy (UGT possibly induced)

  • flaxseed
  • Invokana (canagliflozin)
    +
    flaxseed
    1 interaction

    Monitor/Modify Tx

    canagliflozin + flaxseed

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • flibanserin
  • Invokana (canagliflozin)
    +
    flibanserin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + flibanserin

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • fludrocortisone
  • Invokana (canagliflozin)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fludrocortisone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fluocinolone otic
  • Invokana (canagliflozin)
    +
    fluocinolone otic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fluocinolone otic

    monitor glucose w/ prolonged otic corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fluocinolone topical
  • Invokana (canagliflozin)
    +
    fluocinolone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fluocinolone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fluocinonide topical
  • Invokana (canagliflozin)
    +
    fluocinonide topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fluocinonide topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fluoxetine
  • Invokana (canagliflozin)
    +
    fluoxetine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fluoxetine

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • fluphenazine
  • Invokana (canagliflozin)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fluphenazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • flurandrenolide topical
  • Invokana (canagliflozin)
    +
    flurandrenolide topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + flurandrenolide topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fluticasone propionate topical
  • Invokana (canagliflozin)
    +
    fluticasone propionate topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fluticasone propionate topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fosamprenavir
  • Invokana (canagliflozin)
    +
    fosamprenavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fosamprenavir

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • fosinopril
  • Invokana (canagliflozin)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fosinopril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • foslevodopa
  • Invokana (canagliflozin)
    +
    foslevodopa
    1 interaction

    Monitor/Modify Tx

    canagliflozin + foslevodopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fosphenytoin
  • Invokana (canagliflozin)
    +
    fosphenytoin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + fosphenytoin

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced, antagonistic effects)

  • furosemide
  • Invokana (canagliflozin)
    +
    furosemide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + furosemide

    monitor volume status, renal fxn, BP, glucose: combo may incr. risk of hypovolemia, renal impairment, hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • garlic
  • Invokana (canagliflozin)
    +
    garlic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + garlic

    monitor BP, glucose w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • gilteritinib
  • Invokana (canagliflozin)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + gilteritinib

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ginkgo
  • Invokana (canagliflozin)
    +
    ginkgo
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ginkgo

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (additive effects, antagonistic effects)

  • ginseng, American
  • Invokana (canagliflozin)
    +
    ginseng, American
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ginseng, American

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • ginseng, Asian
  • Invokana (canagliflozin)
    +
    ginseng, Asian
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ginseng, Asian

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • glimepiride
  • Invokana (canagliflozin)
    +
    glimepiride
    1 interaction

    Monitor/Modify Tx

    canagliflozin + glimepiride

    monitor glucose; consider decr. glimepiride dose: combo may incr. risk of hypoglycemia (additive effects)

  • glipizide
  • Invokana (canagliflozin)
    +
    glipizide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + glipizide

    monitor glucose; consider decr. glipizide dose: combo may incr. risk of hypoglycemia (additive effects)

  • glyburide
  • Invokana (canagliflozin)
    +
    glyburide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + glyburide

    monitor glucose; consider decr. glyburide dose: combo may incr. risk of hypoglycemia (additive effects)

  • goserelin
  • Invokana (canagliflozin)
    +
    goserelin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + goserelin

    monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • guanfacine
  • Invokana (canagliflozin)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + guanfacine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • gymnema
  • Invokana (canagliflozin)
    +
    gymnema
    1 interaction

    Monitor/Modify Tx

    canagliflozin + gymnema

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • halcinonide topical
  • Invokana (canagliflozin)
    +
    halcinonide topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + halcinonide topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • halobetasol topical
  • Invokana (canagliflozin)
    +
    halobetasol topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + halobetasol topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • haloperidol
  • Invokana (canagliflozin)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + haloperidol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • hydralazine
  • Invokana (canagliflozin)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydralazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • hydrochlorothiazide
  • Invokana (canagliflozin)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydrochlorothiazide

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • hydrocodone
  • Invokana (canagliflozin)
    +
    hydrocodone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydrocodone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • hydrocortisone
  • Invokana (canagliflozin)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydrocortisone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • hydrocortisone topical
  • Invokana (canagliflozin)
    +
    hydrocortisone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydrocortisone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • hydromorphone
  • Invokana (canagliflozin)
    +
    hydromorphone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydromorphone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • hydroxychloroquine
  • Invokana (canagliflozin)
    +
    hydroxychloroquine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + hydroxychloroquine

    monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

  • iloperidone
  • Invokana (canagliflozin)
    +
    iloperidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + iloperidone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • iloprost
  • Invokana (canagliflozin)
    +
    iloprost
    1 interaction

    Monitor/Modify Tx

    canagliflozin + iloprost

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • imipramine
  • Invokana (canagliflozin)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + imipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • inavolisib
  • Invokana (canagliflozin)
    +
    inavolisib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + inavolisib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • indapamide
  • Invokana (canagliflozin)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + indapamide

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • insulin
  • Invokana (canagliflozin)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + insulin

    monitor glucose; consider dose adjustment of one or both drugs: combo may incr. risk of hypoglycemia (additive effects)

  • irbesartan
  • Invokana (canagliflozin)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + irbesartan

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • iron sucrose
  • Invokana (canagliflozin)
    +
    iron sucrose
    1 interaction

    Monitor/Modify Tx

    canagliflozin + iron sucrose

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • isocarboxazid
  • Invokana (canagliflozin)
    +
    isocarboxazid
    1 interaction

    Monitor/Modify Tx

    canagliflozin + isocarboxazid

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • isoflurane
  • Invokana (canagliflozin)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    canagliflozin + isoflurane

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • isoniazid
  • Invokana (canagliflozin)
    +
    isoniazid
    1 interaction

    Monitor/Modify Tx

    canagliflozin + isoniazid

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • isosorbide dinitrate
  • Invokana (canagliflozin)
    +
    isosorbide dinitrate
    1 interaction

    Monitor/Modify Tx

    canagliflozin + isosorbide dinitrate

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • isosorbide mononitrate
  • Invokana (canagliflozin)
    +
    isosorbide mononitrate
    1 interaction

    Monitor/Modify Tx

    canagliflozin + isosorbide mononitrate

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • isradipine
  • Invokana (canagliflozin)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + isradipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • labetalol
  • Invokana (canagliflozin)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + labetalol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • landiolol
  • Invokana (canagliflozin)
    +
    landiolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + landiolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lanreotide
  • Invokana (canagliflozin)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lanreotide

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (additive effects, antagonistic effects)

  • leuprolide
  • Invokana (canagliflozin)
    +
    leuprolide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + leuprolide

    monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • levobunolol ophthalmic
  • Invokana (canagliflozin)
    +
    levobunolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + levobunolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • levodopa
  • Invokana (canagliflozin)
    +
    levodopa
    1 interaction

    Monitor/Modify Tx

    canagliflozin + levodopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • levofloxacin
  • Invokana (canagliflozin)
    +
    levofloxacin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + levofloxacin

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, including life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

  • levonorgestrel (contraceptive)
  • Invokana (canagliflozin)
    +
    levonorgestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + levonorgestrel (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • levorphanol
  • Invokana (canagliflozin)
    +
    levorphanol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + levorphanol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • levothyroxine
  • Invokana (canagliflozin)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + levothyroxine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • lidocaine
  • Invokana (canagliflozin)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lidocaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • linagliptin
  • Invokana (canagliflozin)
    +
    linagliptin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + linagliptin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • linezolid
  • Invokana (canagliflozin)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    canagliflozin + linezolid

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • liothyronine
  • Invokana (canagliflozin)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + liothyronine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • liraglutide
  • Invokana (canagliflozin)
    +
    liraglutide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + liraglutide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • lisinopril
  • Invokana (canagliflozin)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lisinopril

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • lithium
  • Invokana (canagliflozin)
    +
    lithium
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lithium

    monitor lithium levels: combo may incr. or decr. lithium levels, incr. risk of adverse effects or decr. efficacy (lithium renal excretion possibly altered)

  • lixisenatide
  • Invokana (canagliflozin)
    +
    lixisenatide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lixisenatide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • lopinavir/ritonavir
  • Invokana (canagliflozin)
    +
    lopinavir/ ritonavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lopinavir/ ritonavir

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • lorlatinib
  • Invokana (canagliflozin)
    +
    lorlatinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lorlatinib

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • losartan
  • Invokana (canagliflozin)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + losartan

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • loxapine
  • Invokana (canagliflozin)
    +
    loxapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + loxapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lubiprostone
  • Invokana (canagliflozin)
    +
    lubiprostone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lubiprostone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lumateperone
  • Invokana (canagliflozin)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lumateperone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • lurasidone
  • Invokana (canagliflozin)
    +
    lurasidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lurasidone

    monitor BP, glucose; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • lutetium Lu 177 dotatate
  • Invokana (canagliflozin)
    +
    lutetium Lu 177 dotatate
    1 interaction

    Monitor/Modify Tx

    canagliflozin + lutetium Lu 177 dotatate

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • magnesium sulfate
  • Invokana (canagliflozin)
    +
    magnesium sulfate
    1 interaction

    Monitor/Modify Tx

    canagliflozin + magnesium sulfate

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • maraviroc
  • Invokana (canagliflozin)
    +
    maraviroc
    1 interaction

    Monitor/Modify Tx

    canagliflozin + maraviroc

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mavorixafor
  • Invokana (canagliflozin)
    +
    mavorixafor
    1 interaction

    Monitor/Modify Tx

    canagliflozin + mavorixafor

    monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

  • mecasermin
  • Invokana (canagliflozin)
    +
    mecasermin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + mecasermin

    monitor glucose: combo may incr. risk of severe hypoglycemia (additive effects)

  • medroxyprogesterone (contraceptive)
  • Invokana (canagliflozin)
    +
    medroxyprogesterone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + medroxyprogesterone (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • megestrol
  • Invokana (canagliflozin)
    +
    megestrol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + megestrol

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • meperidine
  • Invokana (canagliflozin)
    +
    meperidine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + meperidine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • mepivacaine
  • Invokana (canagliflozin)
    +
    mepivacaine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + mepivacaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • methadone
  • Invokana (canagliflozin)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + methadone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • methohexital
  • Invokana (canagliflozin)
    +
    methohexital
    1 interaction

    Monitor/Modify Tx

    canagliflozin + methohexital

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • methyldopa
  • Invokana (canagliflozin)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    canagliflozin + methyldopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • methylene blue injection
  • Invokana (canagliflozin)
    +
    methylene blue injection
    1 interaction

    Monitor/Modify Tx

    canagliflozin + methylene blue injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • methylprednisolone
  • Invokana (canagliflozin)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + methylprednisolone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • methyltestosterone
  • Invokana (canagliflozin)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + methyltestosterone

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • metolazone
  • Invokana (canagliflozin)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + metolazone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • metoprolol
  • Invokana (canagliflozin)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + metoprolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • metreleptin
  • Invokana (canagliflozin)
    +
    metreleptin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + metreleptin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • midazolam
  • Invokana (canagliflozin)
    +
    midazolam
    1 interaction

    Monitor/Modify Tx

    canagliflozin + midazolam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • milk thistle
  • Invokana (canagliflozin)
    +
    milk thistle
    1 interaction

    Monitor/Modify Tx

    canagliflozin + milk thistle

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • milrinone
  • Invokana (canagliflozin)
    +
    milrinone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + milrinone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • milsaperidone
  • Invokana (canagliflozin)
    +
    milsaperidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + milsaperidone

    monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • minoxidil
  • Invokana (canagliflozin)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + minoxidil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mirtazapine
  • Invokana (canagliflozin)
    +
    mirtazapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + mirtazapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • moexipril
  • Invokana (canagliflozin)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + moexipril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • molindone
  • Invokana (canagliflozin)
    +
    molindone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + molindone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mometasone topical
  • Invokana (canagliflozin)
    +
    mometasone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + mometasone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • morphine
  • Invokana (canagliflozin)
    +
    morphine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + morphine

    monitor respiratory rate, BP; consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • moxifloxacin
  • Invokana (canagliflozin)
    +
    moxifloxacin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + moxifloxacin

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, including life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

  • nadolol
  • Invokana (canagliflozin)
    +
    nadolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nadolol

    monitor BP, glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia, hypotension, including orthostasis, syncope (additive effects, antagonistic effects)

  • nalbuphine
  • Invokana (canagliflozin)
    +
    nalbuphine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nalbuphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • nateglinide
  • Invokana (canagliflozin)
    +
    nateglinide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nateglinide

    monitor glucose; consider decr. nateglinide dose: combo may incr. risk of hypoglycemia (additive effects)

  • nattokinase
  • Invokana (canagliflozin)
    +
    nattokinase
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nattokinase

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • naxitamab
  • Invokana (canagliflozin)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    canagliflozin + naxitamab

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nebivolol
  • Invokana (canagliflozin)
    +
    nebivolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nebivolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nelfinavir
  • Invokana (canagliflozin)
    +
    nelfinavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nelfinavir

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • nevirapine
  • Invokana (canagliflozin)
    +
    nevirapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nevirapine

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced)

  • niacin (vitamin B3)
  • Invokana (canagliflozin)
    +
    niacin (vitamin B3)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + niacin (vitamin B3)

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • nicardipine
  • Invokana (canagliflozin)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nicardipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nifedipine
  • Invokana (canagliflozin)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nifedipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nimodipine
  • Invokana (canagliflozin)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nimodipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nisoldipine
  • Invokana (canagliflozin)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nisoldipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nitric oxide
  • Invokana (canagliflozin)
    +
    nitric oxide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nitric oxide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nitrite
  • Invokana (canagliflozin)
    +
    nitrite
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nitrite

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • nitroglycerin
  • Invokana (canagliflozin)
    +
    nitroglycerin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nitroglycerin

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • nitroprusside
  • Invokana (canagliflozin)
    +
    nitroprusside
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nitroprusside

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • norelgestromin (contraceptive)
  • Invokana (canagliflozin)
    +
    norelgestromin (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + norelgestromin (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • norepinephrine
  • Invokana (canagliflozin)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + norepinephrine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • norethindrone (contraceptive)
  • Invokana (canagliflozin)
    +
    norethindrone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + norethindrone (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • norgestimate (contraceptive)
  • Invokana (canagliflozin)
    +
    norgestimate (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + norgestimate (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • norgestrel (contraceptive)
  • Invokana (canagliflozin)
    +
    norgestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + norgestrel (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • nortriptyline
  • Invokana (canagliflozin)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    canagliflozin + nortriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • obinutuzumab
  • Invokana (canagliflozin)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    canagliflozin + obinutuzumab

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • octreotide
  • Invokana (canagliflozin)
    +
    octreotide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + octreotide

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (additive effects, antagonistic effects)

  • ofloxacin
  • Invokana (canagliflozin)
    +
    ofloxacin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ofloxacin

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, including life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

  • olanzapine
  • Invokana (canagliflozin)
    +
    olanzapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + olanzapine

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • oliceridine
  • Invokana (canagliflozin)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + oliceridine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • olmesartan medoxomil
  • Invokana (canagliflozin)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + olmesartan medoxomil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • opicapone
  • Invokana (canagliflozin)
    +
    opicapone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + opicapone

    monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • opium
  • Invokana (canagliflozin)
    +
    opium
    1 interaction

    Monitor/Modify Tx

    canagliflozin + opium

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • oxazepam
  • Invokana (canagliflozin)
    +
    oxazepam
    1 interaction

    Monitor/Modify Tx

    canagliflozin + oxazepam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • oxycodone
  • Invokana (canagliflozin)
    +
    oxycodone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + oxycodone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • oxymorphone
  • Invokana (canagliflozin)
    +
    oxymorphone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + oxymorphone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • paliperidone
  • Invokana (canagliflozin)
    +
    paliperidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + paliperidone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • palopegteriparatide
  • Invokana (canagliflozin)
    +
    palopegteriparatide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + palopegteriparatide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • paltusotine
  • Invokana (canagliflozin)
    +
    paltusotine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + paltusotine

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (additive effects, antagonistic effects)

  • pasireotide
  • Invokana (canagliflozin)
    +
    pasireotide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pasireotide

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • pegaspargase
  • Invokana (canagliflozin)
    +
    pegaspargase
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pegaspargase

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • peginterferon alfa 2a
  • Invokana (canagliflozin)
    +
    peginterferon alfa 2a
    1 interaction

    Monitor/Modify Tx

    canagliflozin + peginterferon alfa 2a

    monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or hypoglycemia (additive effects, antagonistic effects)

  • pegvisomant
  • Invokana (canagliflozin)
    +
    pegvisomant
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pegvisomant

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • pentamidine
  • Invokana (canagliflozin)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pentamidine

    monitor BP, glucose: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope; may alter glycemic control, incr. risk of hyperglycemia or severe or life-threatening hypoglycemia (additive effects; antagonistic effects)

  • pentazocine
  • Invokana (canagliflozin)
    +
    pentazocine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pentazocine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • pentobarbital
  • Invokana (canagliflozin)
    +
    pentobarbital
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pentobarbital

    monitor BP, glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (UGT induced; additive effects)

  • perindopril
  • Invokana (canagliflozin)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + perindopril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • perphenazine
  • Invokana (canagliflozin)
    +
    perphenazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + perphenazine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • phenelzine
  • Invokana (canagliflozin)
    +
    phenelzine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + phenelzine

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • phenobarbital
  • Invokana (canagliflozin)
    +
    phenobarbital
    1 interaction

    Monitor/Modify Tx

    canagliflozin + phenobarbital

    monitor BP, glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (UGT induced; additive effects)

  • phenoxybenzamine
  • Invokana (canagliflozin)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + phenoxybenzamine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • phentolamine
  • Invokana (canagliflozin)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + phentolamine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • phenylephrine
  • Invokana (canagliflozin)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + phenylephrine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • phenytoin
  • Invokana (canagliflozin)
    +
    phenytoin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + phenytoin

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced, antagonistic effects)

  • pindolol
  • Invokana (canagliflozin)
    +
    pindolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pindolol

    monitor BP, glucose: combo may decr. antidiabetic agent efficacy; may incr. risk of hypotension, including orthostasis, syncope (additive effects, antagonistic effects)

  • pioglitazone
  • Invokana (canagliflozin)
    +
    pioglitazone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pioglitazone

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • plozasiran
  • Invokana (canagliflozin)
    +
    plozasiran
    1 interaction

    Monitor/Modify Tx

    canagliflozin + plozasiran

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • pramipexole
  • Invokana (canagliflozin)
    +
    pramipexole
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pramipexole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • pramlintide
  • Invokana (canagliflozin)
    +
    pramlintide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pramlintide

    monitor glucose; may need to further adjust coadministered insulin doses: combo may incr. risk of severe hypoglycemia (additive effects)

  • prazosin
  • Invokana (canagliflozin)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + prazosin

    monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • prednicarbate topical
  • Invokana (canagliflozin)
    +
    prednicarbate topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + prednicarbate topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • prednisolone
  • Invokana (canagliflozin)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + prednisolone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • prednisone
  • Invokana (canagliflozin)
    +
    prednisone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + prednisone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • primidone
  • Invokana (canagliflozin)
    +
    primidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + primidone

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced)

  • procarbazine
  • Invokana (canagliflozin)
    +
    procarbazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + procarbazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • prochlorperazine
  • Invokana (canagliflozin)
    +
    prochlorperazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + prochlorperazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • promethazine
  • Invokana (canagliflozin)
    +
    promethazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + promethazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • propafenone
  • Invokana (canagliflozin)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + propafenone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • propofol
  • Invokana (canagliflozin)
    +
    propofol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + propofol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • propranolol
  • Invokana (canagliflozin)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + propranolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • protriptyline
  • Invokana (canagliflozin)
    +
    protriptyline
    1 interaction

    Monitor/Modify Tx

    canagliflozin + protriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • pseudoephedrine
  • Invokana (canagliflozin)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + pseudoephedrine

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • quetiapine
  • Invokana (canagliflozin)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + quetiapine

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • quinapril
  • Invokana (canagliflozin)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + quinapril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • quinidine (antiarrhythmic)
  • Invokana (canagliflozin)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + quinidine (antiarrhythmic)

    monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

  • quinine
  • Invokana (canagliflozin)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + quinine

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • ramipril
  • Invokana (canagliflozin)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ramipril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ranolazine
  • Invokana (canagliflozin)
    +
    ranolazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ranolazine

    monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

  • rasagiline
  • Invokana (canagliflozin)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    canagliflozin + rasagiline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • remifentanil
  • Invokana (canagliflozin)
    +
    remifentanil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + remifentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • remimazolam
  • Invokana (canagliflozin)
    +
    remimazolam
    1 interaction

    Monitor/Modify Tx

    canagliflozin + remimazolam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • repaglinide
  • Invokana (canagliflozin)
    +
    repaglinide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + repaglinide

    monitor glucose; consider decr. repaglinide dose: combo may incr. risk of hypoglycemia (additive effects)

  • ribose
  • Invokana (canagliflozin)
    +
    ribose
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ribose

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • rifampin
  • Invokana (canagliflozin)
    +
    rifampin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + rifampin

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced)

  • riociguat
  • Invokana (canagliflozin)
    +
    riociguat
    1 interaction

    Monitor/Modify Tx

    canagliflozin + riociguat

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • risperidone
  • Invokana (canagliflozin)
    +
    risperidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + risperidone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • ritonavir
  • Invokana (canagliflozin)
    +
    ritonavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ritonavir

    monitor glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy (UGT induced, antagonistic effects)

  • ropinirole
  • Invokana (canagliflozin)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ropinirole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ropivacaine
  • Invokana (canagliflozin)
    +
    ropivacaine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ropivacaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • rosiglitazone
  • Invokana (canagliflozin)
    +
    rosiglitazone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + rosiglitazone

    monitor glucose; consider decr. dose of one or both drugs: combo may incr. risk of hypoglycemia (additive effects)

  • rotigotine transdermal
  • Invokana (canagliflozin)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    canagliflozin + rotigotine transdermal

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • sacrosidase
  • Invokana (canagliflozin)
    +
    sacrosidase
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sacrosidase

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • sacubitril
  • Invokana (canagliflozin)
    +
    sacubitril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sacubitril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • safinamide
  • Invokana (canagliflozin)
    +
    safinamide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + safinamide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • saxagliptin
  • Invokana (canagliflozin)
    +
    saxagliptin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + saxagliptin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • segesterone (contraceptive)
  • Invokana (canagliflozin)
    +
    segesterone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    canagliflozin + segesterone (contraceptive)

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • selegiline
  • Invokana (canagliflozin)
    +
    selegiline
    1 interaction

    Monitor/Modify Tx

    canagliflozin + selegiline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • selegiline transdermal
  • Invokana (canagliflozin)
    +
    selegiline transdermal
    1 interaction

    Monitor/Modify Tx

    canagliflozin + selegiline transdermal

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • semaglutide
  • Invokana (canagliflozin)
    +
    semaglutide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + semaglutide

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • sevoflurane
  • Invokana (canagliflozin)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sevoflurane

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • sildenafil
  • Invokana (canagliflozin)
    +
    sildenafil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sildenafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • silodosin
  • Invokana (canagliflozin)
    +
    silodosin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + silodosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • sirolimus
  • Invokana (canagliflozin)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sirolimus

    monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (P-gp-mediated transport inhibited)

  • sitagliptin
  • Invokana (canagliflozin)
    +
    sitagliptin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sitagliptin

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • sodium ferric gluconate complex
  • Invokana (canagliflozin)
    +
    sodium ferric gluconate complex
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sodium ferric gluconate complex

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • somapacitan
  • Invokana (canagliflozin)
    +
    somapacitan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + somapacitan

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • somatrogon
  • Invokana (canagliflozin)
    +
    somatrogon
    1 interaction

    Monitor/Modify Tx

    canagliflozin + somatrogon

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • somatropin
  • Invokana (canagliflozin)
    +
    somatropin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + somatropin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • sotalol
  • Invokana (canagliflozin)
    +
    sotalol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sotalol

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • sparsentan
  • Invokana (canagliflozin)
    +
    sparsentan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sparsentan

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • spironolactone
  • Invokana (canagliflozin)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + spironolactone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • sucralfate
  • Invokana (canagliflozin)
    +
    sucralfate
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sucralfate

    monitor glucose w/ sucralfate oral suspension: combo may decr. antidiabetic agent efficacy (antagonistic effects, oral suspension contains sorbitol)

  • sufentanil
  • Invokana (canagliflozin)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sufentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • sunitinib
  • Invokana (canagliflozin)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + sunitinib

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • tacrolimus
  • Invokana (canagliflozin)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tacrolimus

    monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited)

  • tadalafil
  • Invokana (canagliflozin)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tadalafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tagraxofusp
  • Invokana (canagliflozin)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tagraxofusp

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • talazoparib
  • Invokana (canagliflozin)
    +
    talazoparib
    1 interaction

    Monitor/Modify Tx

    canagliflozin + talazoparib

    monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

  • tamsulosin
  • Invokana (canagliflozin)
    +
    tamsulosin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tamsulosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tapentadol
  • Invokana (canagliflozin)
    +
    tapentadol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tapentadol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • taurine
  • Invokana (canagliflozin)
    +
    taurine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + taurine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • telmisartan
  • Invokana (canagliflozin)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + telmisartan

    monitor BP, glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (UGT induced; additive effects)

  • temsirolimus
  • Invokana (canagliflozin)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    canagliflozin + temsirolimus

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • tenofovir alafenamide
  • Invokana (canagliflozin)
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tenofovir alafenamide

    if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

  • tenofovir disoproxil
  • Invokana (canagliflozin)
    +
    tenofovir disoproxil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tenofovir disoproxil

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

  • teprotumumab
  • Invokana (canagliflozin)
    +
    teprotumumab
    1 interaction

    Monitor/Modify Tx

    canagliflozin + teprotumumab

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • terazosin
  • Invokana (canagliflozin)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + terazosin

    monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tesamorelin
  • Invokana (canagliflozin)
    +
    tesamorelin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tesamorelin

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • testosterone
  • Invokana (canagliflozin)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + testosterone

    monitor glucose: combo may incr. risk of hypoglycemia (additive effects)

  • thalidomide
  • Invokana (canagliflozin)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + thalidomide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • thioridazine
  • Invokana (canagliflozin)
    +
    thioridazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + thioridazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • thiothixene
  • Invokana (canagliflozin)
    +
    thiothixene
    1 interaction

    Monitor/Modify Tx

    canagliflozin + thiothixene

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • thyroid
  • Invokana (canagliflozin)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    canagliflozin + thyroid

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • timolol
  • Invokana (canagliflozin)
    +
    timolol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + timolol

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • timolol ophthalmic
  • Invokana (canagliflozin)
    +
    timolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    canagliflozin + timolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tipranavir
  • Invokana (canagliflozin)
    +
    tipranavir
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tipranavir

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • tizanidine
  • Invokana (canagliflozin)
    +
    tizanidine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tizanidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tolcapone
  • Invokana (canagliflozin)
    +
    tolcapone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tolcapone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • torsemide
  • Invokana (canagliflozin)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + torsemide

    monitor volume status, renal fxn, BP, glucose: combo may incr. risk of hypovolemia, renal impairment, hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • tramadol
  • Invokana (canagliflozin)
    +
    tramadol
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tramadol

    monitor BP, glucose: combo may incr. risk of severe hypoglycemia, severe hypotension, including orthostasis, syncope (additive effects)

  • trandolapril
  • Invokana (canagliflozin)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    canagliflozin + trandolapril

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • tranylcypromine
  • Invokana (canagliflozin)
    +
    tranylcypromine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + tranylcypromine

    monitor BP, glucose: combo may incr. risk of hypoglycemia, hypotension, including orthostasis, syncope (additive effects)

  • trazodone
  • Invokana (canagliflozin)
    +
    trazodone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + trazodone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • treprostinil
  • Invokana (canagliflozin)
    +
    treprostinil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + treprostinil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • triamcinolone
  • Invokana (canagliflozin)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + triamcinolone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • triamcinolone topical
  • Invokana (canagliflozin)
    +
    triamcinolone topical
    1 interaction

    Monitor/Modify Tx

    canagliflozin + triamcinolone topical

    monitor glucose w/ prolonged topical corticosteroid use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • triamterene
  • Invokana (canagliflozin)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    canagliflozin + triamterene

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

  • trifluoperazine
  • Invokana (canagliflozin)
    +
    trifluoperazine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + trifluoperazine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • trimipramine
  • Invokana (canagliflozin)
    +
    trimipramine
    1 interaction

    Monitor/Modify Tx

    canagliflozin + trimipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • triptorelin
  • Invokana (canagliflozin)
    +
    triptorelin
    1 interaction

    Monitor/Modify Tx

    canagliflozin + triptorelin

    monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • turmeric
  • Invokana (canagliflozin)
    +
    turmeric
    1 interaction

    Monitor/Modify Tx

    canagliflozin + turmeric

    monitor glucose w/ oral turmeric: combo may incr. risk of hypoglycemia (additive effects)

  • ubrogepant
  • Invokana (canagliflozin)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ubrogepant

    limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • valsartan
  • Invokana (canagliflozin)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    canagliflozin + valsartan

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • vamorolone
  • Invokana (canagliflozin)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + vamorolone

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • vardenafil
  • Invokana (canagliflozin)
    +
    vardenafil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + vardenafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • verapamil
  • Invokana (canagliflozin)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    canagliflozin + verapamil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • vorinostat
  • Invokana (canagliflozin)
    +
    vorinostat
    1 interaction

    Monitor/Modify Tx

    canagliflozin + vorinostat

    monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

  • vosoritide
  • Invokana (canagliflozin)
    +
    vosoritide
    1 interaction

    Monitor/Modify Tx

    canagliflozin + vosoritide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • yohimbe
  • Invokana (canagliflozin)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    canagliflozin + yohimbe

    monitor BP, especially w/ high yohimbe doses: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ziprasidone
  • Invokana (canagliflozin)
    +
    ziprasidone
    1 interaction

    Monitor/Modify Tx

    canagliflozin + ziprasidone

    monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

Caution Advised

  • darolutamide
  • Invokana (canagliflozin)
    +
    darolutamide
    1 interaction

    Caution Advised

    canagliflozin + darolutamide

    if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • glecaprevir
  • Invokana (canagliflozin)
    +
    glecaprevir
    1 interaction

    Caution Advised

    canagliflozin + glecaprevir

    caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • naldemedine
  • Invokana (canagliflozin)
    +
    naldemedine
    1 interaction

    Caution Advised

    canagliflozin + naldemedine

    caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • pibrentasvir
  • Invokana (canagliflozin)
    +
    pibrentasvir
    1 interaction

    Caution Advised

    canagliflozin + pibrentasvir

    caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@39e372b1
  • hypersensitivity reaction
  • anaphylaxis
  • acute kidney injury
  • ketoacidosis
  • UTI, serious
  • hypotension, orthostatic
  • pancreatitis
  • bone density loss
  • fractures
  • lower limb amputation risk
  • Fournier gangrene
  • renal cell CA risk

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@78e6cfff
  • hyperkalemia
  • genital mycotic infection
  • cholesterol incr.
  • magnesium incr.
  • hypoglycemia
  • UTI
  • urination incr.
  • phosphate incr.
  • Hgb incr.
  • vulvovaginal pruritus
  • thirst
  • hypotension, orthostatic
  • constipation
  • nausea
  • fatigue
  • Cr incr.
  • lower limb amputation risk

Safety/Monitoring .

Monitoring Parameters
Cr at baseline, then as clinically indicated; BP; consider urine ketones if ketoacidosis risk

Pregnancy/Lactation .

Pregnancy

Clinical Summary

avoid use in 2nd and 3rd trimester, weigh risk/benefit in 1st trimester; inadequate human data available; risk of irreversible adverse effects on renal development and maturation in 2nd and 3rd trimesters based on animal data at 0.5x systemic exposure and drug's mechanism of action; no known risk of teratogenicity in 1st trimester based on animal data at up to 19x recommended human dose

Lactation

Clinical Summary

avoid use while breastfeeding; no human data available, though possible risk of adverse effects on infant renal development and maturation based on drug's mechanism of action; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@10321698

Metabolism: for canagliflozin: liver; CYP450: minimal (7%); 3A4 substrate; UGT: 1A9, 2B4 substrate

Excretion: for canagliflozin: feces 51.7% (41.5% unchanged), urine 33% (<1% unchanged); Half-life: 10.6-13.1h

Subclass: Diabetes: SGLT2 Inhibitors ; SGLT2 Inhibitors, Cardiovascular ; SGLT2 Inhibitors, Nephrological

Mechanism of Action
for canagliflozin: inhibits sodium-glucose cotransporter 2 (SGLT2), reducing glucose and sodium reabsorption, incr. urinary glucose excretion and sodium delivery to distal tubule; may incr. tubuloglomerular feedback and decr. intraglomerular pressure

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Janssen Pharmaceuticals, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@2afef49c

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

oral tablet:

  • 100 mg (30 ea): $564.00
  • 300 mg (30 ea): $564.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information